In vitro activity of Syn-2869, a novel triazole agent, against emerging and less common mold pathogens

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 5, 1999, Pages 1260-1263

  Johnson, Elizabeth M ^a,b   Szekely, Adrien ^a   Warnock, David W ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b NHS BLOOD AND TRANSPLANT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 DIFLUOROPHENYL) 3 [4 [4 [2 (4 TRIFLUOROMETHOXYBENZYL) 2H 1,2,4 TRIAZOL 3 ONE 4 YL]PHENYL]PIPERAZIN 1 YL] 1 (1H 1,2,4 TRIAZOL 1 YL)BUTAN 2 OL; AMPHOTERICIN B; HYALIN; ITRACONAZOLE; SYN 289; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIFUNGAL ACTIVITY; ARTICLE; DRUG EFFICACY; DRUG SENSITIVITY; DRUG STRUCTURE; EXOPHIALA; FUSARIUM SOLANI; MINIMUM INHIBITORY CONCENTRATION; MOULD; MYCOSIS; NONHUMAN; PRIORITY JOURNAL;

EID: 0032937743     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.5.1260     Document Type: Article

References (30)

1. Abel, M. D., Y. Bathini, C. Ha, T. Furukawa, G. Kasitu, J. Khan, R. G. Micetich, D. Q. Nguyen, S. M. Salama, G. Samari, I. Sidhu, P. Spevak, and N. Unemi. 1998. Syn-2869, novel broad-spectrum antifungal triazole: synthesis and structure activity relationships, abstr. F-148, p. 270. In Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
2. Anaissie, E. 1992. Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin. Infect. Dis 14(Suppl. 1):S43-S53.
3. Berenguer, J., J. L. Rodriguez-Tudela, C. Richard, M. Alvarez, M. A. Sanz, L. Gaztelurrutia, J. Ayats, J. V. Martinez-Suarez, and the Scedosporium protificans Spanish Study Group. 1997. Deep infections caused by Scedosporium prolificans: a report on 16 cases in Spain and a review of the literature. Medicine 76:256-265.
4. Denning, D. W., J. Y. Lee, J. S. Hostetler, P. Pappas, C. A. Kauffman, D. H. Dewsnup, J. N. Galgiani, J. R. Graybill, A. M. Sugar, A. Catanzaro, H. Gallis, J. R. Perfect, B. Dockery, W. E. Dismukes, and D. A. Stevens. 1994. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am. J. Med. 97:135-144.
5. Denning, D. W., S. A. Radford, K. L. Oakley, L. Hall, E. M. Johnson, and D. W. Warnock. 1997. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J. Antimicrob. Chemother. 40:401-414.
6. Espinel-Ingroff, A. 1998. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbiol. 36:198-202.
7. Espinel-Ingroff, A. 1998. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 36:2950-2956.
8. Espinel-Ingroff, A., M. Bartlett, R. Bowden, N. X. Chin, C. Cooper, Jr., A. Fothergill, M. R. McGinnis, P. Menezes, S. A. Messer, P. W. Nelson, F. C. Odds, L. Pasarell, J. Peter, M. A. Pfaller, J. H. Rex, M. G. Rinaldi, G. S. Shankland, T. J. Walsh, and I. Weitzman. 1997. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J. Clin. Microbiol. 35:139-143.
9. Fothergill, A. W., S. M. Salama, and M. G. Rinaldi. 1998. An in vitro head-to-head comparison of Syn2836, Syn2869, Syn2903, Syn2921, amphotericin B, fluconazole, and itraconazole against a spectrum of 90 clinically-significant fungi, abstr. J-117, p. 484. In Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
10. Furukawa, T., H. Saito, T. Uji, K. Nishida, F. Higashitani, N. Unemi, and H. Yamaguchi. 1998. In vivo activity of Syn2869, a novel antifungal triazole in murine models of deep mycosis, abstr. F-149, p. 270. In Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
11. Gallis, H. A., R. H. Drew, and W. W. Pickard. 1990. Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. 12:308-329.
12. Garnis, A. S., T. Gudnason, G. S. Giebink, and N. K. C. Ramsay. 1991. Disseminated infection with Fusarium in recipients of bone marrow transplants. Rev. Infect. Dis. 13:1077-1088.
13. Gibb, A. P., and H. Van Den Elzen. 1998. Activity of Syn2869, fluconazole, and itraconazole against 139 consecutive yeast isolates from normally-sterile sites, abstr. F-147, p. 270. In Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
14. Johnson, E. M., A. Szekely, and D. W. Warnock. 1998. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J. Antimicrob. Chemother. 42:741-745.
15. Khan, J. K., H. Montaseri, M. Poglod, H. Z. Bu, S. Salama, R. G. Micetich, and M. Daneshtalab. 1998. Pharmacokinetics and oral bioavailability of novel triazole derivative Syn2869 - a potent new antifungal agent and its comparison with itraconazole, abstr. F-152, p. 271. In Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
16. Lister, J. 1996. Amphotericin B lipid complex (Abelcet) in the treatment of invasive mycoses: the North American experience. Eur. J. Haematol. 56 (Suppl. 57):18-23.
17. Lutwick, L. I., J. N. Galgiani, R. H. Johnson, and D. A. Stevens. 1976. Visceral fungal infections due to Petriellidium boydii (Allesheria boydii). In vitro drug sensitivity studies. Am. J. Med. 61:632-640.
18. McGinnis, M. R., and L. Pasarell. 1998. In vitro testing of susceptibilities of filamentous ascomycetes to voriconazole, itraconazole, and amphotericin B, with consideration of phylogenetic implications. J. Clin. Microbiol. 36:2353-2355.
19. Morrison, V. A., R. J. Haake, and D. J. Weisdorf. 1994. Non-Candida fungal infections after bone marrow transplantation: risk factors and outcome. Am. J. Med. 96:497-503.
20. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. Document M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
21. Ng, T. C., and D. W. Denning. 1995. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Arch. Intern. Med. 155:1093-1098.
22. Odds, F. C., F. Van Gerven, A. Espinel-Ingroff, M. S. Bartlett, M. A. Ghannoum, M. V. Lancaster, M. A. Pfaller, J. H. Rex, M. G. Rinaldi, and T. J. Walsh. 1998. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob. Agents Chemother. 42:282-288.
23. Oppenheim, B. A., R. Herbrecht, and S. Kusne. 1995. The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clin. Infect. Dis. 21:1145-1153.
24. Pujol, I., J. Guarro, J. Gene, and J. Sala. 1997. In-vitro antifungal susceptibility of clinical and environmental Fusarium spp. strains. J. Antimicrob. Chemother. 39:163-167.
25. Radford, S. A., E. M. Johnson, and D. W. Warnock. 1997. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob. Agents Chemother. 41:841-843.
26. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, and A. Barry for the Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole and candida infections. Clin. Infect. Dis. 24:235-247.
27. Salama, S. M., H. Atwal, A. Gandhi, J. Khan, H. Montaseri, M. Poglod, R. G. Micetich, and M. Daneshtalab. 1998. Syn2869, a new potent antifungal triazole: in vivo efficacy against systemic infections of Torulopsis glabrata and Cryptococcus neoformans in immunosuppressed mice, abstr. F-151, p. 271. In Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
28. Salama, S. M., A. Gandhi, H. Atwal, J. Simon, J. Khan, R. G. Micetich, and M. Daneshtalab. 1998. Syn2869, a new potent antifungal triazole for the treatment of systemic and superficial fungal infections: in vitro activity against clinical isolates of yeast and dermatphytes [sic], abstr. F-150, p. 270. In Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
29. Sharkey, P. K., J. R. Graybill, M. G. Rinaldi. D. A. Stevens, R. M. Tucker, J. D. Peterie, P. D. Hoeprich, D. L. Greer, L. Frenkel, G. W. Counts, J. Goodrich, S. Zellner, R. W. Bradsher, C. M. van der Horst, K. Israel, G. A. Pankey, and C. P. Barranco. 1990. Itraconazole treatment of phaeohyphomycosis. J. Am. Acad. Dermatol. 23:577-586.
30. Vartivarian, S. E., E. J. Anaissie, and G. P. Bodey. 1993. Emerging fungal pathogens in immunocompromised patients: classification, diagnosis, and management. Clin. Infect. Dis. 17(Suppl. 2):S487-S491.